22 completed, 16 terminated, 3 withdrawn, 2 recruiting. 35 Phase 2, 14 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Stem Cell Infusion: new trials by email Literature Review of Stem Cell Infusion trials Research Report on Stem Cell Infusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis CD 34 and MSC infusion, Standard of care for Cirrhosis management - Cirrhosis, Liver | Phase 4 | Completed | Asian Institute of Gastroenterology, India | 5 | 2019-07-01 | 2020-10-22 |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Palifermin, Panobinostat, Gemcitabine - Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2017-06-01 | 2017-04-21 | |
| Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease ATG, fludarabine, cyclophosphamide - Sickle Cell Disease | Phase 2 | Recruiting | University of Illinois at Chicago | 50 | 2017-03-20 | 2026-07-08 |
| Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas Radiation therapy, Temozolomide, Stem cell collection - Astrocytoma, Brainstem Glioma | Early Phase 1 | Withdrawn | Washington University School of Medicine | 2017-01-01 | 2017-02-20 | |
| Autologous Stem Cell Study for Adult TBI (Phase 2b) Placebo Infusion, Autologous BMMNC Infusion - Brain Injuries, Traumatic, Brain Injuries, Acute | Phase 2 | Unknown | The University of Texas Health Science Center, Houston | 37 | 2016-11-21 | 2024-05-09 |
| URMC Related Haplo-identical Donor BMT Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide - Hematological Disease, Immune Deficiencies | Phase 1 | Completed | University of Rochester | 74 | 2015-10-01 | 2021-11-03 |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Busulfan, Fludarabine, Clofarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 11 | 2015-09-14 | 2024-02-22 |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib Bortezomib, Melphalan, Neupogen - AL Amyloidosis | Phase 3 | Terminated | Boston Medical Center | 3 | 2015-06-01 | 2018-09-10 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - T-cell Non-Hodgkin Lymphoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2013-07-01 | 2023-01-30 |
| Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation Bortezomib, Carmustine, Etoposide - Multiple Myeloma | Phase 2 | Terminated | Washington University School of Medicine | 10 | 2012-09-01 | 2014-10-15 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Fludarabine monophosphate, Busulfan, Stem Cell Infusion - Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 201 | 2012-04-11 | 2023-06-29 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2012-02-01 | 2016-03-17 |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Fludarabine, Clofarabine, Busulfan - Disorder Related to Bone Marrow Transplantation, Leukemia | Phase 3 | Completed | M.D. Anderson Cancer Center | 256 | 2011-11-02 | 2021-12-16 |
| Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Stem cell infusion - Critical Limb Ischemia (CLI) | Phase 1 / Phase 2 | Terminated | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 20 | 2011-09-01 | 2018-12-19 |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies Vorinostat, Gemcitabine, Busulfan - Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 78 | 2011-08-01 | 2015-11-18 |
| A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias Natural Killer (NK) Cell Infusion, Stem Cell Infusion - Leukemia, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2011-01-29 | 2019-08-22 |
| Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant G-CSF, AMD3100, Leukapheresis - Stem Cell Transplant Patients | Phase 1 | Completed | Washington University School of Medicine | 29 | 2010-04-29 | 2017-01-25 |
Showing 20 of 45. Sign in to see all of them.
Multiple Myeloma (13) · Leukemia (10) · Hodgkin Disease (9) · Lymphoma (9) · Myelodysplastic Syndromes (9) · Leukemia, Myeloid, Acute (8) · Lymphoma, Non-Hodgkin (8) · Neoplasms, Plasma Cell (6) · Immunoglobulin Light-chain Amyloidosis (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Anemia, Aplastic (3) · Anemia, Sickle Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Graft vs Host Disease (2)
M.D. Anderson Cancer Center (16) · Baylor College of Medicine (7) · Washington University School of Medicine (5) · Boston Medical Center (4) · Masonic Cancer Center, University of Minnesota (3) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Asian Institute of Gastroenterology, India (1) · Augusta University (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · The University of Texas Health Science Center, Houston (1) · University of Illinois at Chicago (1) · University of Rochester (1)
United States (41) · India (1) · Spain (1)
Robert Krance, MD (3) · Vaishali Sanchorawala, MD (3) · Muzaffar H. Qazilbash, MD (2) · Ravi Vij, M.D. (2) · Richard E. Champlin, MD (2) · Angela Smith, MD (1) · Bernat Soria (1) · Charles S Cox, MD (1) · Damiano Rondelli, MD (1) · Daniel J. Weisdorf, MD (1) · Issa F. Khouri, MD,BS (1) · James E Carroll, M.D. (1) · Jeffrey Andolina, MD (1) · Jian Li Campian, M.D., Ph.D. (1) · John DiPersio, M.D., Ph.D. (1)
PMID 20946966, PMID 21454450, PMID 23721329, PMID 25452614, PMID 26071868, PMID 29476021, PMID 30389035, PMID 30644983, PMID 30826465, PMID 33951890, PMID 35068788